Disease-Specific Allocations: The Past Decade Of Venture, IPOs, And Deal-making

Figuring out what disease areas are attracting the most venture funding and deal-related capital in startup and emerging biotech has historically been quite challenging as few if any datasets track it comprehensively. But late last week, on the eve of BIO, a significant piece of analysis should shine some light [...]